top of page
Gyala Therapeutics unveils first-in-class CAR-T therapy targeting CD84 showing strong preclinical efficacy in hard-to-treat leukemias
Hospital Clinic and IDIBAPS have significant experience and know-how on preclinical and clinical development of CAR T cell products and in the treatment of haematological malignancies.
​
​
The scientists and clinicians involved in Gyala have developed ARI-0001, a CART targeting CD19 that has been approved by the Spanish regulatory agency, and ARI-0002, a CART targeting BCMA currently in clinical development.
bottom of page